X4 Pharmaceuticals Inc
XFOR5.335USD
+5.145+2707.89%
收盤 04/28, 16:00（美東）報價延遲15分鐘
912.00M總市值
虧損本益比TTM
關於 X4 Pharmaceuticals Inc 公司
X4 Pharmaceuticals, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於發現和開發用於治療罕見疾病和治療選擇有限的疾病的新型療法，重點是治療由免疫系統功能障礙引起的疾病。其主要臨牀候選藥物是 mavorixafor，一種趨化因子受體 CXCR4 的小分子選擇性拮抗劑，正在開發爲口服、每日一次的療法。該公司已經開發了一系列趨化因子受體 CXC 受體 4 型 (CXCR4) 的小分子口服拮抗劑。該公司有兩種臨牀前候選藥物：X4P-003，一種第二代 CXCR4 拮抗劑，旨在具有比 mavorixafor 更強的特性，可能爲 CXCR4 依賴性疾病和原發性免疫缺陷提供機會，以及 X4P-002，一種具有分佈特徵和已證實能夠穿過血腦屏障的 CXCR4 拮抗劑。
公司簡介
公司代碼XFOR
公司名稱X4 Pharmaceuticals Inc
上市日期Nov 16, 2017
成立日期2010
CEODr. Paula Ragan, Ph.D.
員工數量143
證券類型Ordinary Share
年結日Nov 16
公司地址61 North Beacon Street
城市BOSTON
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編02134
電話18575298300
網址https://www.x4pharma.com/
公司代碼XFOR
上市日期Nov 16, 2017
成立日期2010
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Paula Ragan, Ph.D.
Dr. Paula Ragan, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
36.25K
-67.42%
Dr. Mary Dibiase, Ph.D.
Dr. Mary Dibiase, Ph.D.
Chief Operating Officer
Chief Operating Officer
35.21K
+159.96%
Dr. Christophe Arbet-engels, Ph.D.
Dr. Christophe Arbet-engels, Ph.D.
Chief Medical Officer
Chief Medical Officer
28.81K
+5.98K%
Mr. Mark Baldry
Mr. Mark Baldry
Chief Commercial Officer
Chief Commercial Officer
4.31K
-82.28%
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
2.56K
-36.98%
Dr. Gary J. Bridger, Ph.D.
Dr. Gary J. Bridger, Ph.D.
Director
Director
1.72K
-46.55%
Mr. David W.J. Mcgirr
Mr. David W.J. Mcgirr
Independent Director
Independent Director
--
--
Dr. Murray W. Stewart, M.D.
Dr. Murray W. Stewart, M.D.
Director
Director
--
--
Ms. Francoise De Craecker
Ms. Francoise De Craecker
Independent Director
Independent Director
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
Managing Director
Managing Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Paula Ragan, Ph.D.
Dr. Paula Ragan, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
36.25K
-67.42%
Dr. Mary Dibiase, Ph.D.
Dr. Mary Dibiase, Ph.D.
Chief Operating Officer
Chief Operating Officer
35.21K
+159.96%
Dr. Christophe Arbet-engels, Ph.D.
Dr. Christophe Arbet-engels, Ph.D.
Chief Medical Officer
Chief Medical Officer
28.81K
+5.98K%
Mr. Mark Baldry
Mr. Mark Baldry
Chief Commercial Officer
Chief Commercial Officer
4.31K
-82.28%
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
2.56K
-36.98%
Dr. Gary J. Bridger, Ph.D.
Dr. Gary J. Bridger, Ph.D.
Director
Director
1.72K
-46.55%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 2月23日 週日
更新時間: 2月23日 週日
持股股東
股東類型
持股股東
股東統計
佔比
Bain Capital Life Sciences Investors, LLC
9.74%
New Enterprise Associates (NEA)
8.63%
BlackRock Institutional Trust Company, N.A.
5.91%
The Vanguard Group, Inc.
4.72%
Acorn Capital Advisors, LLC
4.21%
Other
66.79%
持股股東
股東統計
佔比
Bain Capital Life Sciences Investors, LLC
9.74%
New Enterprise Associates (NEA)
8.63%
BlackRock Institutional Trust Company, N.A.
5.91%
The Vanguard Group, Inc.
4.72%
Acorn Capital Advisors, LLC
4.21%
Other
66.79%
股東類型
股東統計
佔比
Investment Advisor
25.05%
Investment Advisor/Hedge Fund
11.85%
Venture Capital
8.63%
Hedge Fund
5.73%
Private Equity
4.92%
Individual Investor
2.32%
Research Firm
1.96%
Bank and Trust
0.09%
Pension Fund
0.04%
Other
39.41%
機構持股
更新時間: 3月5日 週三
更新時間: 3月5日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
216
105.29M
60.63%
-54.29M
2024Q4
216
103.66M
60.78%
-53.08M
2024Q3
212
110.90M
65.83%
-43.36M
2024Q2
209
114.19M
68.28%
-40.11M
2024Q1
203
115.38M
69.15%
-30.64M
2023Q4
192
109.42M
65.98%
-32.86M
2023Q3
189
132.64M
89.63%
+450.20K
2023Q2
191
133.25M
115.52%
+52.30M
2023Q1
171
81.27M
73.10%
+5.35M
2022Q4
172
79.41M
72.57%
+27.33M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Bain Capital Life Sciences Investors, LLC
16.92M
9.74%
--
--
Dec 31, 2024
New Enterprise Associates (NEA)
14.99M
8.63%
--
--
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
10.26M
5.91%
-93.42K
-0.90%
Dec 31, 2024
The Vanguard Group, Inc.
8.20M
4.72%
-239.83K
-2.84%
Dec 31, 2024
Acorn Capital Advisors, LLC
7.31M
4.21%
--
--
Dec 31, 2024
OrbiMed Advisors, LLC
7.13M
4.11%
--
--
Dec 31, 2024
Kingdon Capital Management, L.L.C.
4.94M
2.84%
+298.32K
+6.43%
Dec 31, 2024
Geode Capital Management, L.L.C.
3.50M
2.01%
+49.70K
+1.44%
Dec 31, 2024
AXA Investment Managers UK Ltd.
3.07M
1.77%
-4.80K
-0.16%
Dec 31, 2024
State Street Global Advisors (US)
3.06M
1.76%
+104.40K
+3.54%
Dec 31, 2024
查看更多
持股ETF
更新時間: 4月6日 週日
更新時間: 4月6日 週日
機構名稱
佔比
iShares Micro-Cap ETF
0.01%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Value ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
Simplify Propel Opportunities ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
查看更多
iShares Micro-Cap ETF
佔比0.01%
ProShares UltraPro Russell2000
佔比0%
iShares Russell 2000 Value ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
Simplify Propel Opportunities ETF
佔比0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
Invesco NASDAQ Future Gen 200 ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據